JP7797423B2 - ヘテロ二量体リラキシン融合物及びその使用 - Google Patents
ヘテロ二量体リラキシン融合物及びその使用Info
- Publication number
- JP7797423B2 JP7797423B2 JP2022577390A JP2022577390A JP7797423B2 JP 7797423 B2 JP7797423 B2 JP 7797423B2 JP 2022577390 A JP2022577390 A JP 2022577390A JP 2022577390 A JP2022577390 A JP 2022577390A JP 7797423 B2 JP7797423 B2 JP 7797423B2
- Authority
- JP
- Japan
- Prior art keywords
- relaxin
- chain
- fusion
- heterodimeric
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/64—Relaxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2221—Relaxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025279747A JP2026053559A (ja) | 2020-06-17 | 2025-12-24 | ヘテロ二量体リラキシン融合物及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063040250P | 2020-06-17 | 2020-06-17 | |
| US63/040,250 | 2020-06-17 | ||
| PCT/EP2021/066309 WO2021255127A1 (en) | 2020-06-17 | 2021-06-16 | Heterodimeric relaxin fusions and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025279747A Division JP2026053559A (ja) | 2020-06-17 | 2025-12-24 | ヘテロ二量体リラキシン融合物及びその使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023530335A JP2023530335A (ja) | 2023-07-14 |
| JP2023530335A5 JP2023530335A5 (https=) | 2024-09-19 |
| JPWO2021255127A5 JPWO2021255127A5 (https=) | 2024-09-19 |
| JP7797423B2 true JP7797423B2 (ja) | 2026-01-13 |
Family
ID=76584509
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022577390A Active JP7797423B2 (ja) | 2020-06-17 | 2021-06-16 | ヘテロ二量体リラキシン融合物及びその使用 |
| JP2025279747A Pending JP2026053559A (ja) | 2020-06-17 | 2025-12-24 | ヘテロ二量体リラキシン融合物及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025279747A Pending JP2026053559A (ja) | 2020-06-17 | 2025-12-24 | ヘテロ二量体リラキシン融合物及びその使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US11795205B2 (https=) |
| EP (1) | EP4168434A1 (https=) |
| JP (2) | JP7797423B2 (https=) |
| KR (1) | KR20230024994A (https=) |
| CN (1) | CN115916813B (https=) |
| AR (1) | AR125007A1 (https=) |
| AU (3) | AU2021290997C1 (https=) |
| BR (1) | BR112022025019A2 (https=) |
| CA (1) | CA3186143A1 (https=) |
| CL (1) | CL2022003578A1 (https=) |
| CO (1) | CO2023000038A2 (https=) |
| CR (1) | CR20230015A (https=) |
| EC (1) | ECSP23002960A (https=) |
| IL (1) | IL298786A (https=) |
| MX (1) | MX2022016340A (https=) |
| TW (1) | TWI899263B (https=) |
| WO (1) | WO2021255127A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023086913A2 (en) * | 2021-11-11 | 2023-05-19 | Tectonic Therapeutic, Inc. | Relaxin-2 fusion protein analogs and methods of using same |
| EP4524156A4 (en) | 2022-05-07 | 2025-10-22 | Beijing Tuo Jie Biopharmaceutical Co Ltd | RELAXIN FUSION PROTEIN OR ANALOGUE AND ITS MEDICAL USE |
| US20260103501A1 (en) * | 2022-07-15 | 2026-04-16 | Nutcracker Therapeutics, Inc. | MRNA Therapies Including SIRP-ALPHA |
| TW202438534A (zh) | 2022-12-09 | 2024-10-01 | 瑞典商阿斯特捷利康公司 | 使用異二聚物鬆弛素融合體的給藥方案 |
| AU2024232947A1 (en) | 2023-03-03 | 2025-10-16 | Astrazeneca Ab | Pharmaceutical formulation comprising heterodimeric relaxin fusion proteins and uses thereof |
| KR20260035823A (ko) | 2023-05-18 | 2026-03-13 | 테크토닉 오퍼레이팅 컴퍼니 인코포레이티드 | 렐락신-2 융합 단백질 유사체 및 이를 사용하는 방법 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014522641A (ja) | 2011-07-01 | 2014-09-08 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | リラキシン融合ポリペプチドおよびその使用 |
| JP2014533243A (ja) | 2011-11-04 | 2014-12-11 | ザイムワークス，インコーポレイテッド | Ｆｃドメインにおける変異を有する安定なヘテロ二量体抗体デザイン |
| WO2017100540A2 (en) | 2015-12-09 | 2017-06-15 | The California Institute For Biomedical Research | Relaxin immunoglobulin fusion proteins and methods of use |
| JP2020505029A (ja) | 2017-01-25 | 2020-02-20 | メディミューン，エルエルシー | リラキシン融合ポリペプチドおよびその使用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| US8389475B2 (en) * | 2009-08-10 | 2013-03-05 | The Board Of Trustees Of The Leland Stanford Junior University | Relaxin analogs |
| PL2635607T3 (pl) * | 2010-11-05 | 2020-05-18 | Zymeworks Inc. | Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC |
| AR094147A1 (es) * | 2012-12-27 | 2015-07-15 | Bayer Pharma Aktiengellschaft | Polipeptidos de fusion con actividad de relaxina y sus usos |
| RU2729467C2 (ru) * | 2014-05-28 | 2020-08-06 | Займворкс Инк. | Модифицированные антигенсвязывающие полипептидные конструкции и их применение |
-
2021
- 2021-06-16 MX MX2022016340A patent/MX2022016340A/es unknown
- 2021-06-16 IL IL298786A patent/IL298786A/en unknown
- 2021-06-16 CN CN202180042080.5A patent/CN115916813B/zh active Active
- 2021-06-16 KR KR1020237001632A patent/KR20230024994A/ko active Pending
- 2021-06-16 EP EP21734103.1A patent/EP4168434A1/en active Pending
- 2021-06-16 BR BR112022025019A patent/BR112022025019A2/pt unknown
- 2021-06-16 AU AU2021290997A patent/AU2021290997C1/en active Active
- 2021-06-16 WO PCT/EP2021/066309 patent/WO2021255127A1/en not_active Ceased
- 2021-06-16 CA CA3186143A patent/CA3186143A1/en active Pending
- 2021-06-16 US US17/348,825 patent/US11795205B2/en active Active
- 2021-06-16 CR CR20230015A patent/CR20230015A/es unknown
- 2021-06-16 JP JP2022577390A patent/JP7797423B2/ja active Active
- 2021-06-17 TW TW110122051A patent/TWI899263B/zh active
- 2021-06-17 AR ARP210101647A patent/AR125007A1/es unknown
-
2022
- 2022-12-15 CL CL2022003578A patent/CL2022003578A1/es unknown
-
2023
- 2023-01-03 CO CONC2023/0000038A patent/CO2023000038A2/es unknown
- 2023-01-16 EC ECSENADI20232960A patent/ECSP23002960A/es unknown
- 2023-07-01 US US18/346,205 patent/US12187774B2/en active Active
-
2024
- 2024-01-05 AU AU2024200074A patent/AU2024200074B2/en active Active
- 2024-11-25 US US18/958,082 patent/US20250230214A1/en active Pending
-
2025
- 2025-10-20 AU AU2025252658A patent/AU2025252658A1/en active Pending
- 2025-12-24 JP JP2025279747A patent/JP2026053559A/ja active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014522641A (ja) | 2011-07-01 | 2014-09-08 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | リラキシン融合ポリペプチドおよびその使用 |
| JP2014533243A (ja) | 2011-11-04 | 2014-12-11 | ザイムワークス，インコーポレイテッド | Ｆｃドメインにおける変異を有する安定なヘテロ二量体抗体デザイン |
| WO2017100540A2 (en) | 2015-12-09 | 2017-06-15 | The California Institute For Biomedical Research | Relaxin immunoglobulin fusion proteins and methods of use |
| JP2020505029A (ja) | 2017-01-25 | 2020-02-20 | メディミューン，エルエルシー | リラキシン融合ポリペプチドおよびその使用 |
Non-Patent Citations (1)
| Title |
|---|
| Ha JH et al.，Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins，Front Immunol，2016年，vol. 7:394，pp. 1-16 |
Also Published As
| Publication number | Publication date |
|---|---|
| TWI899263B (zh) | 2025-10-01 |
| US20240025958A1 (en) | 2024-01-25 |
| CN115916813B (zh) | 2026-03-24 |
| ECSP23002960A (es) | 2023-03-31 |
| CR20230015A (es) | 2023-02-17 |
| AU2024200074B2 (en) | 2025-11-27 |
| BR112022025019A2 (pt) | 2022-12-27 |
| AU2021290997B2 (en) | 2023-10-12 |
| JP2023530335A (ja) | 2023-07-14 |
| AU2025252658A1 (en) | 2025-11-13 |
| CL2022003578A1 (es) | 2023-06-09 |
| TW202214673A (zh) | 2022-04-16 |
| WO2021255127A1 (en) | 2021-12-23 |
| US11795205B2 (en) | 2023-10-24 |
| AR125007A1 (es) | 2023-05-31 |
| IL298786A (en) | 2023-02-01 |
| KR20230024994A (ko) | 2023-02-21 |
| JP2026053559A (ja) | 2026-03-25 |
| CA3186143A1 (en) | 2021-12-23 |
| MX2022016340A (es) | 2023-01-24 |
| CN115916813A (zh) | 2023-04-04 |
| EP4168434A1 (en) | 2023-04-26 |
| AU2021290997A1 (en) | 2023-02-09 |
| AU2024200074A1 (en) | 2024-01-25 |
| US20220017591A1 (en) | 2022-01-20 |
| US20250230214A1 (en) | 2025-07-17 |
| AU2021290997C1 (en) | 2024-01-04 |
| US12187774B2 (en) | 2025-01-07 |
| CO2023000038A2 (es) | 2023-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7797423B2 (ja) | ヘテロ二量体リラキシン融合物及びその使用 | |
| US11845782B2 (en) | Relaxin fusion polypeptides and uses thereof | |
| JP7387431B2 (ja) | 神経ペプチドｙ受容体の調節因子としての抗体結合環状ペプチドチロシンチロシン化合物 | |
| EP3896083B1 (en) | Fc fusion proteins comprising novel linkers or arrangements | |
| JP7064618B2 (ja) | 増殖分化因子１５アゴニスト化合物およびその使用方法 | |
| US20250295737A1 (en) | Treatment Using Heterodimeric Relaxin Fusions | |
| CN106496331A (zh) | 一种新型FSH‑Fc融合蛋白及其制备方法和用途 | |
| TW202426037A (zh) | 使用異二聚鬆弛素融合物之治療方法 | |
| EA049488B1 (ru) | Гетеродимерные слитые продукты на основе релаксина и пути их применения | |
| EA052557B1 (ru) | Лечение с применением гетеродимерных слитых продуктов на основе релаксина | |
| CN118434437A (zh) | 使用异源二聚体松弛素融合物进行的治疗 | |
| HK1244016B (zh) | FC融合高亲和力IGE受体α链 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20231222 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240603 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240603 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240909 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250624 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250908 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20251125 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20251224 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7797423 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |